Showing 8261-8270 of 8783 results for "".
- FDA Accepts Investigational New Drug Application for Alphaeon's Neurotoxin Evosyalhttps://practicaldermatology.com/news/20140909-fda_accepts_investigational_new_drug_application_for_alphaeons_neurotoxin_evosyal/2459123/The FDA accepted the Investigational New Drug (IND) Application to conduct clinical studies for EVOSYAL, an botulinum toxin Type A neurotoxin that was acquired by Alphaeon last year as part of the acquisition of Evolus Inc. “The product development team
- Alphaeon to Acquire Clarion Medical Technologieshttps://practicaldermatology.com/news/20140909-alphaeon_to_acquire_clarion_medical_technologies/2459125/Alphaeon Corporation, a subsidiary of Strathspey Crown Holdings LLC, and Clarion Medical Technologies Inc. entered into a definitive agreement for Alphaeon to acquire all of the outstanding shares and assets of Clarion, a provider of medical and aesthetic equipment and consumabl
- Goldfaden MD Named 2014 CPG Editor's Choice Award Finalist by Informa's SupplySidehttps://practicaldermatology.com/news/20140908-goldfaden_md_named_2014_cpg_editors_choice_award_finalist_by_informas_supplyside/2459126/Informa Exhibitions has named Light Treatment “Dark Spot Corrector” as one of its finalists for the 2014 SupplySide CPG Editor's Choice Awards. Five 2013 consumer packaged goods (CPG) products were selected by the SupplySide editorial team for achievements in innovation and market impact in 20 dif
- FDA Approves Keytruda for Advanced Melanomahttps://practicaldermatology.com/news/20140904-fda_approves_keytruda_for_advanced_melanoma/2459129/The FDA granted accelerated approval to Keytruda (pembrolizumab) for treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs.Keytruda is the first approved drug that blocks a cellular pathway known as PD-1, which restricts the
- Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agencyhttps://practicaldermatology.com/news/20140904-amgen_submits_marketing_authorization_application_for_talimogene_laherparepvec_to_the_european_medicines_agency/2459130/Amgen recently submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic. Talimogen
- Advanced Dermatology and Cosmetic Surgery (ADCS Clinics) Announces the Acquisition of Fort Collins Skin Clinichttps://practicaldermatology.com/news/20140903-advanced_dermatology_and_cosmetic_surgery_adcs_clinics_announces_the_acquisition_of_fort_collins_skin_clinic/2459132/ADCS Clinics (“ADCS”) announced it has completed the acquisition of Fort Collins Skin Clinic in Fort Collins, Colorado; a dermatology practice owned by Dr. Brad Baack and Dr. Andy Kalajian (both Board Certified Dermatologist and fellowship trained Mohs Micrographic Surgeons). Baack and Kalajian, wit
- Modernizing Medicine Announces Inaugural EMA Nation Users Conferencehttps://practicaldermatology.com/news/20140903-modernizing_medicine_announces_inaugural_ema_nation_users_conference/2459133/Modernizing Medicine, Inc., creator of the Electronic Medical Assistant (EMA), announces its inaugural EMA Nation Users Conference. The conference will provide a venue for users of this specialty-specific electronic health record (EHR) system to network and learn how to use EMA's expanding capabilit
- Dermira Completes $51 Million Financing and Expands Management Team and Board of Directorshttps://practicaldermatology.com/news/20140821-dermira_completes_51_million_financing_and_expands_management_team_and_board_of_directors/2459139/Dermira, a specialty biopharmaceutical focused on dermatology, completed a $51 million Series C financing. Existing investors Bay City Capital, New Enterprise Associates (NEA), Canaan Partners and UCB S.A. were joined by new investors Apple Tree Partners, Aisling Capital, Rock S
- Novan's Nitricil™ Technology Shows Efficacy Against Multidrug Resistant Superbugshttps://practicaldermatology.com/news/20140820-novans_nitricil_technology_shows_efficacy_against_multidrug_resistant_superbugs/2459140/Novan Therapeutics' Nitricil™ platform technology has been shown to be efficacious against several of the most multi-drug resistant pathogens plaguing civilian and military health care providers across the globe, according to new data. The
- Acyclovir Muco-Adhesive Buccal Tablet Offers a Novel Approach to Target HSVhttps://practicaldermatology.com/news/20140820-acyclovir_muco-adhesive_buccal_tablet_offers_a_novel_approach_to_target_hsv/2459141/Sitavig® (50mg acyclovir) Muco-Adhesive Buccal Tablet is a new treatment option for recurrent herpes labialis, offering a unique vehicle and delivery system. Sitavig, licensed to Innocutis by BioAlliance Pharma, uses proprietary Lauriad® delivery technology, which delivers a high and sustained conce